Eli Lilly and (NYSE:LLY) Lowered to Buy at StockNews.com

Eli Lilly and (NYSE:LLYGet Rating) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday.

Other equities analysts have also recently issued research reports about the company. Berenberg Bank raised their price target on Eli Lilly and from $270.00 to $305.00 and gave the company a “buy” rating in a report on Monday, December 20th. Barclays raised their price target on Eli Lilly and from $280.00 to $325.00 and gave the company an “overweight” rating in a report on Monday, December 20th. DZ Bank upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $291.00 price target on the stock in a report on Friday, January 21st. BMO Capital Markets raised their price target on Eli Lilly and from $311.00 to $320.00 and gave the company an “outperform” rating in a report on Thursday, December 16th. Finally, Mizuho reduced their target price on Eli Lilly and from $302.00 to $293.00 and set a “buy” rating on the stock in a report on Friday, February 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and currently has an average rating of “Buy” and a consensus price target of $297.39.

Shares of LLY stock traded down $5.41 during trading hours on Wednesday, hitting $302.67. 2,467,831 shares of the company’s stock were exchanged, compared to its average volume of 2,959,952. The stock’s 50-day moving average is $268.98 and its 200-day moving average is $257.77. The company has a debt-to-equity ratio of 1.68, a current ratio of 1.23 and a quick ratio of 0.97. The stock has a market cap of $288.25 billion, a price-to-earnings ratio of 49.29, a price-to-earnings-growth ratio of 2.52 and a beta of 0.43. Eli Lilly and has a 52 week low of $178.58 and a 52 week high of $314.00.

Eli Lilly and (NYSE:LLYGet Rating) last announced its earnings results on Thursday, February 3rd. The company reported $2.49 EPS for the quarter, missing the consensus estimate of $2.51 by ($0.02). The business had revenue of $8 billion for the quarter, compared to the consensus estimate of $7.89 billion. Eli Lilly and had a return on equity of 96.36% and a net margin of 19.71%. Eli Lilly and’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.75 EPS. Equities research analysts forecast that Eli Lilly and will post 8.75 earnings per share for the current fiscal year.

In related news, major shareholder Lilly Endowment Inc sold 139,045 shares of Eli Lilly and stock in a transaction that occurred on Friday, April 8th. The stock was sold at an average price of $310.79, for a total value of $43,213,795.55. Following the sale, the insider now owns 105,573,810 shares of the company’s stock, valued at approximately $32,811,284,409.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Marschall S. Runge bought 202 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was purchased at an average cost of $246.78 per share, for a total transaction of $49,849.56. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 1,088,551 shares of company stock worth $307,943,730. 0.12% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Morgan Stanley grew its stake in Eli Lilly and by 8.2% in the second quarter. Morgan Stanley now owns 3,822,819 shares of the company’s stock valued at $877,414,000 after purchasing an additional 289,490 shares in the last quarter. CMH Wealth Management LLC grew its stake in Eli Lilly and by 1.5% in the third quarter. CMH Wealth Management LLC now owns 19,704 shares of the company’s stock valued at $4,553,000 after purchasing an additional 298 shares in the last quarter. Jag Capital Management LLC grew its stake in Eli Lilly and by 3,919.3% in the third quarter. Jag Capital Management LLC now owns 52,975 shares of the company’s stock valued at $12,240,000 after purchasing an additional 51,657 shares in the last quarter. Emfo LLC bought a new position in Eli Lilly and in the third quarter valued at approximately $58,000. Finally, Newbridge Financial Services Group Inc. grew its stake in Eli Lilly and by 256.7% in the third quarter. Newbridge Financial Services Group Inc. now owns 560 shares of the company’s stock valued at $129,000 after purchasing an additional 403 shares in the last quarter. 82.16% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.